Biosynthesis of Cannabinoids Market- Global Market Analysis and Forecast (2021-2027) Trends, Statistics, Dynamics, Segmentation by Type, Application, End-user, and Region

Biosynthesis of Cannabinoids Market was valued at US$ 16.71 Bn. in 2021. The global Biosynthesis of Cannabinoids Market size is expected to grow at a CAGR of 15.2 % through the forecast period.

Biosynthesis of Cannabinoids Market Overview:

Cannabinoids are majorly found in the cannabis plant. The cannabinoids are produced by the biosynthesis process. Moreover, the biosynthesis procedure is not more chosen, it has the potential to change the way cannabinoids are manufactured in the upcoming future. The two main cannabinoids are delta9tetrahydrocannabinol (THC) and cannabidiol (CBD). The most commonly known of the two is delta9tetrahydrocannabinol (THC), which is the chemical that is responsible for the psychoactive effects of cannabis. Therefore, most cannabinoids are tetrahydrocannabinol (THC), the main compound of cannabis. Synthetic cannabinoids are artificial and contain a wide variety of chemicals, including classic cannabinoids associated with THC and non-classical cannabinoids, including aminoalkylindoles. Synthetic cannabinoids have emerged as new treatments for spasticity and inflammation. Synthetic cannabinoids are used as a treatment for diseases such as arthritis and acute and chronic pain. Biosynthesis of Cannabinoids Market To know about the Research Methodology :- Request Free Sample Report 2021 is considered as a base year to forecast the market from 2022 to 2027. 2020’s market size is estimated on real numbers and outputs of the key players and major players across the globe. The past five years' trends are considered while forecasting the market through 2027. 2020 is a year of exception and analysis, especially with the impact of lockdown by region.

Biosynthesis of Cannabinoids Market Dynamics:

Cannabinoids are a natural compound found in the cannabis plant, also known as Cannabis sativa. In more recent times, these compounds can be synthesized in the laboratory using enzymatic reactions of materials from artificial sources or extracted from plants. The key drivers for the biosynthesis of the cannabinoid market are: Treatment of various diseases: medical cannabis is cannabis and cannabinoids that are prescribed by physicians for their patients. The use of cannabis as medicine has not been rigorously tested due to production and governmental restrictions resulting in limited clinical research to define the safety and efficacy of using cannabis to treat diseases. Primarily evidence has indicated that cannabis might reduce nausea and vomiting during chemotherapy and reduce chronic pain and muscle spasms. The cannabis plant has a history of medicinal use dating back thousands of years in many cultures. Some American medical organizations have requested the removal of cannabis from the list of schedule I controlled substances maintained by the US federal government, followed by a regulatory and scientific review. The increased use of cannabinoids for treatment purposes can help the biosynthesis of the cannabinoid market grow. Cost-effective: Due to its variety of use and medicinal benefits, natural plant products like leaves, seeds, and flowers are expensive. To produce 2g of cannabis requires about 10kg of cannabis plants. And biosynthetic cannabinoids are cost-effective compared to the natural process. Thus, the large environmental impact of cannabinoid production may act as a determining factor in biosynthetic cannabinoid production. Extracting cannabinoid biosynthetically and exporting it as a raw product for various medicinal purposes will help in a rapid increase in the biosynthesis of the cannabinoid market. The restraints for the biosynthesis of the cannabinoid market are: Strict Government rules for the production of cannabis: the strict rules for the production of the cannabis plant and increased demand for medicinal purposes have led to increased costs of the plant. Different countries have various stringent rules regarding the production of the plant, and due to this, the plant production is limited in many parts of the world. Hence this indirectly affects the biosynthesis of the cannabinoid market adversely. Adverse drug reaction of cannabinoids: Artificially synthesized cannabinoids have their own set of side effects. It is said to have side effects like paranoia, heart palpitations, extreme anxiety, seizures, etc., which its natural counterpart does not when used for strictly medicinal purposes. Concurrent consumption of alcohol and marijuana can increase unpleasant effects, including nausea, vomiting, and feelings of panic, anxiety, and paranoia, acting as a major inhibitory factor and slowing the growth of cannabinoid biosynthesis. Covid-19 impact on Biosynthesis of cannabinoid market: In March 2020, the World Health Organization announced the COVID-19 as the emergence in healthcare. The coronavirus was announced as a pandemic, and the government had to impose lockdown and ban flights in many countries to control the spread of the disease. Hence the demand for medical cannabis has increased during the outbreak of research and development activities. Researchers have focused on developing a vaccine to treat COVID-19 using these products, showing a positive results; the market shares her expected to come to a normal state by end of the pandemic. Developments in the biosynthesis of the cannabinoid market: Cannabinoid biosynthesis, which uses simple living Organisms to produce desired compounds at scale, is at a potential tipping point Canadian investment bank ATB capital believes his technology will substantially improve the economics for the production of rare cannabinoids, which it adds will open the gates for pharmaceutical and consumer pack goods (CPG) companies to use them as key inputs for products in the health, wellness, and recreational segments. Solving the key challenges of producing high-quality products on a regular substantial basis at scale looks to be near. Cronos comes out, which has partnered with Ginkgo Bio works successfully to ferment cannabigerol at a research scale and is expected to commercialize products in Sept 2021.

Biosynthesis of Cannabinoids Market Segment Analysis:

Based on Type: The Biosynthesis of Cannabinoids Market is segmented into balanced CBD & THC, Cannabigerol dominant, CBD dominant, and THC dominant. Having the balanced THC and CBD segments hold a big market share CBD cannabidiol and THC (tetrahydrocannabinol) are the most common cannabidiol found in cannabis products. THC and CBD are in both cannabis and hemp. Cannabis contains much more THC than hemp while has a lot of CBDs. Based on application: The Biosynthesis of Cannabinoids Market is segmented into pain management, anxiety management, appetite stimulation, and nausea management. The cannabinoid drug is mostly used for treating psychotic diseases. Mostly the drugs which are being manufactured are used for anxiety management and this holds 35% of the market share over other medicinal use. Hence the anxiety management segment is rising compared to other segments. Based on End-user: The market is segmented into medical purposes, recreational purposes, and research and development. The medical segment holds a large market share. Cannabis has potential medicinal and medicinal properties associated with many compounds, especially delta9tetrahydrocannabinol and cannabidiol. Biosynthesis of Cannabinoids Market

Biosynthesis of Cannabinoids Market Regional Insights:

The North America region dominated the market with the highest percentage of share in 2021. The Asia-Pacific region is expected to witness a 9.8% CAGR during the forecast period. This is mainly due to the increase in disposable income in these countries and the rate of urbanization. The objective of the report is to present a comprehensive analysis of the global Biosynthesis of Cannabinoids Market to the stakeholders in the market. The past and current status of the market with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the market with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the market to the decision-makers. The reports also help in understanding the Biosynthesis of Cannabinoids Market dynamic, and structure by analyzing the market segments and projecting the Biosynthesis of Cannabinoids Market size. Clear representation of competitive analysis of key players by product type, price, financial position, product portfolio, growth strategies, and regional presence in the Biosynthesis of Cannabinoids Market make the report investor’s guide.

Biosynthesis of Cannabinoids Market Scope: Inquiry Before Buying

Biosynthesis of Cannabinoids Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US$ 16.71 Bn.
Forecast Period 2022 to 2027 CAGR: 15.2% Market Size in 2027: US$ 45 Bn.
Segments Covered: by Type • Balanced CBD and THC • Cannabigerol • CBD dominant • THC Dominant
by Application • Anxiety management • Pain management • Appetite stimulation • Nausea management
by End-user • Medicinal use • Research and development use • Recreational use

Biosynthesis of Cannabinoids Market by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Biosynthesis of Cannabinoids Market Key Players

• Hyasynth Biologicals • Amyris Inc • Demetrix • Jazz pharmaceuticals • Lygos • Renew Biopharma • CB Therapeutics • Canopy Growth Corp • Zymergen Inc • Cronos Group Inc • Ginko Bioworks • Creo • Constellation Brands Inc • Evolva Holding SA • Willow Bioscience Inc • InMed Pharmaceuticals • Purisys • Renew Pharma Frequently Asked Questions: 1] What segments are covered in the Global Biosynthesis of Cannabinoids Market report? Ans. The segments covered in the Biosynthesis of Cannabinoids Market report are based on Type, Application, and End User. 2] Which region is expected to hold the highest share in the Global Biosynthesis of Cannabinoids Market? Ans. The North America region is expected to hold the highest share in the Biosynthesis of Cannabinoids Market. 3] What is the market size of the Global Biosynthesis of Cannabinoids Market by 2027? Ans. The market size of the Biosynthesis of Cannabinoids Market by 2027 is expected to reach US$ 45 Bn. 4] What is the forecast period for the Global Biosynthesis of Cannabinoids Market? Ans. The forecast period for the Biosynthesis of Cannabinoids Market is 2021-2027. 5] What was the market size of the Global Biosynthesis of Cannabinoids Market in 2021? Ans. The market size of the Biosynthesis of Cannabinoids Market in 2021 was valued at US$ 16.71 Bn.
1. Global Biosynthesis of Cannabinoids Market Size: Research Methodology 2. Global Biosynthesis of Cannabinoids Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Biosynthesis of Cannabinoids Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Biosynthesis of Cannabinoids Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Biosynthesis of Cannabinoids Market Size Segmentation 4.1. Global Biosynthesis of Cannabinoids Market Size, by Type (2021-2027) • Balanced CBD and THC • Cannabigerol • CBD dominant • THC dominant 4.2. Global Biosynthesis of Cannabinoids Market Size, by Application (2021-2027) • Anxiety Management • Pain management • Appetite management • Nausea management 4.3. Global Biosynthesis of Cannabinoids Market Size, by End User (2021-2027) • Medical use • Research and development use • Recreational use 5. North America Biosynthesis of Cannabinoids Market (2021-2027) 5.1. North America Biosynthesis of Cannabinoids Market Size, by Type (2021-2027) 5.1.1. Balanced CBD and THC 5.1.2. Cannabigerol 5.1.3. CBD dominant 5.1.4. THC dominant 5.2. North America Biosynthesis of Cannabinoids Market Size, by Application (2021-2027) • Anxiety Management • Pain management • Appetite management • Nausea management 5.3. North America Biosynthesis of Cannabinoids Market Size, by End User (2021-2027) • Medical use • Research and development use • Recreational use 5.4. North America Semiconductor Memory Market, by Country (2021-2027) • United States • Canada • Mexico 6. European Biosynthesis of Cannabinoids Market (2021-2027) 6.1. European Biosynthesis of Cannabinoids Market, by Type (2021-2027) 6.2. European Biosynthesis of Cannabinoids Market, by Application (2021-2027) 6.3. European Biosynthesis of Cannabinoids Market, by End User (2021-2027) 6.4. European Biosynthesis of Cannabinoids Market, by Country (2021-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Biosynthesis of Cannabinoids Market (2021-2027) 7.1. Asia Pacific Biosynthesis of Cannabinoids Market, by Type (2021-2027) 7.2. Asia Pacific Biosynthesis of Cannabinoids Market, by Application (2021-2027) 7.3. Asia Pacific Biosynthesis of Cannabinoids Market, by End User (2021-2027) 7.4. Asia Pacific Biosynthesis of Cannabinoids Market, by Country (2021-2027) • China • India • Japan • South Korea • Australia • ASIANAN • Rest Of APAC 8. Middle East and Africa Biosynthesis of Cannabinoids Market (2021-2027) 8.1. Middle East and Africa Biosynthesis of Cannabinoids Market, by Type (2021-2027) 8.2. Middle East and Africa Biosynthesis of Cannabinoids Market, by Application (2021-2027) 8.3. Middle East and Africa Biosynthesis of Cannabinoids Market, by End User (2021-2027) 8.4. Middle East and Africa Biosynthesis of Cannabinoids Market, by Country (2021-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Biosynthesis of Cannabinoids Market (2021-2027) 9.1. South America Biosynthesis of Cannabinoids Market, by Type (2021-2027) 9.2. South America Biosynthesis of Cannabinoids Market, by Application (2021-2027) 9.3. South America Biosynthesis of Cannabinoids Market, by End User (2021-2027) 9.4. South America Biosynthesis of Cannabinoids Market, by Country (2021-2027) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Hyasynth Biologicals 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Amyris Inc 10.3. Demetrix 10.4. Jazz pharmaceuticals 10.5. Lygoes 10.6. Renew Biopharma 10.7. CB Therapeutics 10.8. Canopy Growth Corp 10.9. Zynergen Inc 10.10. Cronos Group Inc 10.11. GinkgoGinko Bioworks 10.12. Creo 10.13. Constellation Brands Inc 10.14. Evolva Holding SA 10.15. Willow Bioscience Inc 10.16. InMed Pharmaceuticals 10.17. Purisys
  • INQUIRE BEFORE BUYING